Volume : 11, Issue : 08, August – 2024

Title:

ADVANCES IN MEDICAL MANAGEMENT OF DIABETES

Authors :

Elham Yahya Baamer, Raghad Ahmed Alsharif, Shatha Abdulrauf Yousef, Abdulaziz Mashuj Alanazi, Saad Mahmoud Tobaigi, Mohammed Hassan A Alothayqi, Lina Zaki Al Nasrallah, Wadha Essa A Aldossari, Zahra Saeed Al Asmari, Lujainah Sami Basubrain, Malak Hussain Asiri, Zeyad Shujaa Ali Almatrafi, Hamoud Obaidallah Humud Almatrafi,Mustafa Ahmed Aljawhari

Abstract :

Introduction: Diabetes mellitus (DM) is a growing global epidemic that is causing a significant socioeconomic burden on nations. Since the traditional methods of treatment have significant side effects and have not addressed the disease’s underlying causes, new strategies for managing diabetes mellitus are emerging quickly. Therefore, in order to create a clinical management plan that is strong, effective, and safe, the issues with each of these techniques must be resolved. The best possible metabolic management of blood pressure, glucose, and body weight is necessary, and improving diet, increasing physical activity, and reducing body weight all require the right information and assistance.
Aim of the study: This narrative review discusses various treatment plans, developments in the management of diabetes mellitus, and related challenges.
Methodology: The review is comprehensive research of PUBMED since year1995 to 2024.
Conclusion: Significant advancements in the treatment of diabetes mellitus have shown encouraging outcomes through the application of several therapeutic approaches, such as medical nutrition therapy, gene therapy, stem cell, nanotechnology, and lifestyle change. Nevertheless, there have been many difficulties in applying these techniques, such as optimizing them to guarantee the best possible blood pressure, cholesterol, and glucose regulation to reduce complications; enhancing patient adherence to pharmacological and lifestyle interventions; safety; ethical concerns; and developing an efficient delivery system, among other difficulties.
Keywords – Diabetes mellitus, gene therapy, advance monitoring and drug delivery

Cite This Article:

Please cite this article in press Elham Yahya Baamer et al., Advances In Medical Management Of Diabetes.,Indo Am. J. P. Sci, 2024; 11 (08).

Number of Downloads : 10

References:

1. Hossain M J, Al‐Mamun M, & Islam M R (2024). Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Science Reports, 7(3), e2004.
2. Sugandh F N U, Chandio M, Raveena F N U, Kumar L, Karishma F N U, Khuwaja S, & Kumar S (2023). Advances in the management of diabetes mellitus: a focus on personalized medicine. Cureus, 15(8).
3. Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson B J, & Lernmark Å (2017). Type 1 diabetes mellitus. Nature reviews Disease primers, 3(1), 1-17.
4. Goyal S, Rani J, Bhat M A, & Vanita V (2023). Genetics of diabetes. World Journal of Diabetes, 14(6), 656.
5. Zajec A, Trebušak Podkrajšek K, Tesovnik T, Šket R, Čugalj Kern B, Jenko Bizjan B, & Kovač J (2022). Pathogenesis of type 1 diabetes: established facts and new insights. Genes, 13(4), 706.
6. Kyvik K O, Green A, & Beck-Nielsen H (1995). Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. Bmj, 311(7010), 913-917.
7. Subramanian S, Khan F, & Hirsch I B (2024). New advances in type 1 diabetes. bmj, 384..
8. Mujeeb-U-Rahman M, Nazari M H, Sencan M, & Antwerp W V (2019). A novel needle-injectable millimeter scale wireless electrochemical glucose sensing platform for artificial pancreas applications. Scientific reports, 9(1), 17421.
9. Fridell J A, Stratta R J, & Gruessner A C (2023). Pancreas transplantation: current challenges, considerations, and controversies. The Journal of Clinical Endocrinology & Metabolism, 108(3), 614-623.
10. Walker J T, Saunders D C, Brissova M, & Powers A C (2021). The human islet: mini-organ with mega-impact. Endocrine reviews, 42(5), 605-657.
11. Palmer S C, Mavridis D, Nicolucci A, Johnson D W, Tonelli M, Craig J C, & Strippoli G F (2016). Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. Jama, 316(3), 313-324.
12. Diabetes Control and Complications Trial Research Group. (1997). Hypoglycemia in the diabetes control and complications trial. Diabetes, 46(2), 271-286.
13. Davies M J, Aroda V R, Collins B S, Gabbay R A, Green J, Maruthur N M, & Buse J B (2022). Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care, 45(11), 2753-2786.
14. Matthews D R, Paldánius P M, Proot P, Chiang Y, Stumvoll M, & Del Prato S (2019). Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. The Lancet, 394(10208), 1519-1529.
15. UK Prospective Diabetes Study (UKPDS) Group. (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet, 352(9131), 854-865.
16. Keller D M, Ahmed N, Tariq H, Walgamage M, Walgamage T, Mohammed A, & Straburzyńska-Migaj E (2022). SGLT2 inhibitors in type 2 diabetes mellitus and heart failure—a concise review. Journal of Clinical Medicine, 11(6), 1470.
17. Heerspink H J, Stefánsson B V, Correa-Rotter R, Chertow G M, Greene T, Hou F F & Wheeler D C (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436-1446.
18. Chong K, Chang J K J, & Chuang L M (2024). Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. The Kaohsiung Journal of Medical Sciences, 40(3), 212-220.
19. Aloke, C., Egwu, C. O., Aja, P. M., Obasi, N. A., Chukwu, J., Akumadu, B. O., … & Achilonu, I. (2022). Current advances in the management of diabetes mellitus. Biomedicines, 10(10), 2436.
20. Jastreboff A M, & Kushner, R F (2023). New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics. Annual review of medicine, 74(1), 125-139.
21. Rosenstock J, & Del Prato S (2022). Basal weekly insulins: the way of the future!. Metabolism, 126, 154924.